17β-Estradiol attenuates hypoxic pulmonary hypertension via estrogen receptor-mediated effects

American Journal of Respiratory and Critical Care Medicine

Volumn 185, Issue 9, 2012, Pages 965-980

  Lahm, Tim ^a   Albrecht, Marjorie ^a   Fisher, Amanda J ^a   Selej, Mona ^a   Patel, Neel G ^a   Brown, Jordan A ^a   Justice, Matthew J ^a   Brown, M Beth ^a   Van Demark, Mary ^a   Trulock, Kevin M ^a   Dieudonne, Dino ^a   Reddy, Jagadeshwar G ^a   Presson, Robert G ^a   Petrache, Irina ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 AMINOBENZOTRIAZOLE; 3,5 DINITROPYROCATECHOL; CYCLIN DEPENDENT KINASE INHIBITOR 1B; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; AUTOPHAGY; CARDIOPULMONARY HEMODYNAMICS; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; FEMALE; HEART RIGHT VENTRICLE; HEART VENTRICLE REMODELING; HYPOXIA; HYPOXIC PULMONARY HYPERTENSION; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; UPREGULATION;

AIRWAY REMODELING; ANIMALS; ANOXIA; BLOOD PRESSURE; CARDIAC OUTPUT; CYCLIN-DEPENDENT KINASE INHIBITOR P27; ESTRADIOL; ESTRADIOL ANTAGONISTS; HYPERTENSION, PULMONARY; LUNG; MALE; NEOVASCULARIZATION, PATHOLOGIC; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ESTROGEN; VENTRICULAR REMODELING;

EID: 84860634134     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201107-1293OC     Document Type: Article

References (80)

1. Hoeper MM, Barbera JA, Channick RN, Hassoun PM, Lang IM, Manes A, Martinez FJ, Naeije R, Olschewski H, Pepke-Zaba J, et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol 2009;54:S85-S96.
2. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54:S43-S54.
3. Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res 2006; 99:675-691. (Pubitemid 44498302)
4. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 2009;297:L1013-L1032.
5. Pak O, Aldashev A, Welsh D, Peacock A. The effects of hypoxia on the cells of the pulmonary vasculature. Eur Respir J 2007;30:364-372. (Pubitemid 47201724)
6. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, Gunther A, Walmrath D, Seeger W, Grimminger F. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002;360:895-900. (Pubitemid 35283832)
7. Blanco I, Gimeno E, Munoz PA, Pizarro S, Gistau C, Rodriguez-Roisin R, Roca J, Barbera JA. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit Care Med 2010;181:270-278.
8. Stolz D, Rasch H, Linka A, Di Valentino M, Meyer A, Brutsche M, Tamm M. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 2008;32:619-628.
9. Moore LG, Reeves JT. Pregnancy blunts pulmonary vascular reactivity in dogs. Am J Physiol 1980;239:H297-H301. (Pubitemid 10010893)
10. Fuchs KI, Moore LG, Rounds S. Pulmonary vascular reactivity is blunted in pregnant rats. J Appl Physiol 1982;53:703-707. (Pubitemid 12027244)
11. Lahm T, Patel KM, Crisostomo PR, Markel TA, Wang M, Herring C, Meldrum DR. Endogenous estrogen attenuates pulmonary artery vasoreactivity and acute hypoxic pulmonary vasoconstriction: the effects of sex and menstrual cycle. Am J Physiol Endocrinol Metab 2007;293: E865-E871. (Pubitemid 47359001)
12. Earley S, Resta TC. Estradiol attenuates hypoxia-induced pulmonary endothelin-1 gene expression. Am J Physiol Lung Cell Mol Physiol 2002;283:L86-L93. (Pubitemid 34764544)
13. Resta TC, Kanagy NL, Walker BR. Estradiol-induced attenuation of pulmonary hypertension is not associated with altered eNOS expression. Am J Physiol Lung Cell Mol Physiol 2001;280:L88-L97.
14. Lahm T, Crisostomo PR, Markel TA, Wang M, Weil BR, Novotny NM, Meldrum DR. The effects of estrogen on pulmonary artery vasoreactivity and hypoxic pulmonary vasoconstriction: potential new clinical implications for an old hormone. Crit Care Med 2008;36: 2174-2183.
15. Pugh ME, Hemnes AR. Pulmonary hypertension in women. Expert Rev Cardiovasc Ther 2010;8:1549-1558.
16. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-oh kinase. Nature 2000;407:538-541.
17. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, Tujague M, Strom A, Treuter E, Warner M, et al. Estrogen receptors: how do they signal and what are their targets. Physiol Rev 2007;87: 905-931. (Pubitemid 47084672)
18. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science 2005;308:1583-1587. (Pubitemid 40807497)
19. Billon-Gales A, Fontaine C, Douin-Echinard V, Delpy L, Berges H, Calippe B, Lenfant F, Laurell H, Guery JC, Gourdy P, et al. Endothelial estrogen receptor-alpha plays a crucial role in the atheroprotective action of 17beta-estradiol in low-density lipoprotein receptor-deficient mice. Circulation 2009;120:2567-2576.
20. Chambliss KL, Yuhanna IS, Anderson RG, Mendelsohn ME, Shaul PW. ERbeta has nongenomic action in caveolae. Mol Endocrinol 2002;16: 938-946. (Pubitemid 34478532)
21. Chen Z, Yuhanna IS, Galcheva-Gargova Z, Karas RH, Mendelsohn ME, Shaul PW. Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest 1999;103:401-406. (Pubitemid 29069990)
22. Tofovic SP, Salah EM, Mady HH, Jackson EK, Melhem MF. Estradiol metabolites attenuate monocrotaline-induced pulmonary hypertension in rats. J Cardiovasc Pharmacol 2005;46:430-437. (Pubitemid 41407569)
23. Austin ED, Cogan JD, West JD, Hedges LK, Hamid R, Dawson EP, Wheeler LA, Parl FF, Loyd JE, Phillips JA III. Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females. Eur Respir J 2009;34: 1093-1099.
24. Dubey RK, Gillespie DG, Zacharia LC, Rosselli M, Imthurn B, Jackson EK. Methoxyestradiols mediate the antimitogenic effects of locally applied estradiol on cardiac fibroblast growth. Hypertension 2002;39: 412-417. (Pubitemid 34165158)
25. Tofovic SP, Zhang X, Jackson EK, Dacic S, Petrusevska G. 2-methoxyestradiol mediates the protective effects of estradiol in monocrotalineinduced pulmonary hypertension. Vascul Pharmacol 2006;45:358-367. (Pubitemid 44765298)
26. Lahm T, Crisostomo PR, Markel TA, Wang M, Wang Y, Tan J, Meldrum DR. Selective estrogen receptor-{alpha} and estrogen receptor-{beta} agonists rapidly decrease pulmonary artery vasoconstriction by a nitric oxide-dependent mechanism. Am J Physiol Regul Integr Comp Physiol 2008;295:R1486-R1493.
27. Morecroft I, Doyle B, Nilsen M, Kolch W, Mair K, Maclean MR. Mice lacking the raf-1 kinase inhibitor protein exhibit exaggerated hypoxiainduced pulmonary hypertension. Br J Pharmacol 2011;163:948-963.
28. Yu L, Quinn DA, Garg HG, Hales CA. Cyclin-dependent kinase inhibitor p27kip1, but not p21waf1/cip1, is required for inhibition of hypoxia-induced pulmonary hypertension and remodeling by heparin in mice. Circ Res 2005;97:937-945. (Pubitemid 41552680)
29. Lee SJ, Smith A, Guo L, Alastalo TP, Li M, Sawada H, Liu X, Chen ZH, Ifedigbo E, Jin Y, et al. Autophagic protein LC3B confers resistance against hypoxia-induced pulmonary hypertension. Am J Respir Crit Care Med 2010;183:649-658.
30. Lahm T, Albrecht M, Adamowicz J, Van Demark M, Devlin C, Ivan M, Presson RG, Petrache I. Effects of 17-beta estradiol on cultured hypoxic lung endothelial cells and hypoxic pulmonary hypertension. Am J Respir Crit Care Med 2010;181:A5227.
31. Lahm T, Albrecht M, Justice M, Fisher A, Van Demark M, Patel N, Presson RG, Petrache I. 17-beta estradiol (E2) attenuates hypoxiainduced pulmonary hypertension through an estrogen receptordependent, but E2 metabolite- independent mechanism. Am J Respir Crit Care Med 2011;183:A2521.
32. Hsu JT, Kan WH, Hsieh CH, Choudhry MA, Schwacha MG, Bland KI, Chaudry IH. Mechanism of estrogen-mediated attenuation of hepatic injury following trauma-hemorrhage: Akt-dependent HO-1 upregulation. J Leukoc Biol 2007;82:1019-1026. (Pubitemid 47511062)
33. Umar S, Iorga A, Matori H, Nadadur RD, Li J, Maltese F, van der Laarse A, Eghbali M. Estrogen rescues pre-existing severe pulmonary hypertension in rats. Am J Respir Crit Care Med 2011;184:715-723.
34. Bergstrom M, Lu L, Marquez M, Moulder R, Jacobsson G, Ogren M, Eriksson B, Watanabe Y, Langstrom B. Catechol-o-methyltransferase inhibition increases the uptake of 11c-3-(3,4-dihydroxyphenyl)-lalanine in the rat pancreas. Scand J Gastroenterol 1996;31:1216-1222. (Pubitemid 26403098)
35. Balani SK, Zhu T, Yang TJ, Liu Z, He B, Lee FW. Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in rats, dogs, and monkeys. Drug Metab Dispos 2002;30:1059-1062.
36. Crosby A, Jones FM, Southwood M, Stewart S, Schermuly R, Butrous G, Dunne DW, Morrell NW. Pulmonary vascular remodeling correlates with lung eggs and cytokines in murine schistosomiasis. Am J Respir Crit Care Med 2010;181:279-288.
37. Handoko ML, de Man FS, Happe CM, Schalij I, Musters RJ, Westerhof N, Postmus PE, Paulus WJ, van der Laarse WJ, Vonk-Noordegraaf A. Opposite effects of training in rats with stable and progressive pulmonary hypertension. Circulation 2009;120:42-49.
38. Haddad F, Doyle R, Murphy DJ, Hunt SA. Right ventricular function in cardiovascular disease. Part II: Pathophysiology, clinical importance, and management of right ventricular failure. Circulation 2008;117: 1717-1731. (Pubitemid 351482595)
39. Partovian C, Adnot S, Eddahibi S, Teiger E, Levame M, Dreyfus P, Raffestin B, Frelin C. Heart and lung VEGF mRNA expression in rats with monocrotaline- or hypoxia-induced pulmonary hypertension. Am J Physiol 1998;275:H1948-H1956.
40. Chaouat A, Bugnet AS, Kadaoui N, Schott R, Enache I, Ducolone A, Ehrhart M, Kessler R, Weitzenblum E. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:189-194. (Pubitemid 40981192)
41. Hoshikawa Y, Nana-Sinkam P, Moore MD, Sotto-Santiago S, Phang T, Keith RL, Morris KG, Kondo T, Tuder RM, Voelkel NF, et al. Hypoxia induces different genes in the lungs of rats compared with mice. Physiol Genomics 2003;12:209-219. (Pubitemid 37139700)
42. Guo J, Krause DN, Horne J, Weiss JH, Li X, Duckles SP. Estrogenreceptor- mediated protection of cerebral endothelial cell viability and mitochondrial function after ischemic insult in vitro. J Cereb Blood Flow Metab 2010;30:545-554.
43. Mercier I, Mader S, Calderone A. Tamoxifen and ICI 182,780 negatively influenced cardiac cell growth via an estrogen receptor-independent mechanism. Cardiovasc Res 2003;59:883-892. (Pubitemid 38366244)
44. Xu DQ, Luo Y, Liu Y, Wang J, Zhang B, Xu M, Wang YX, Dong HY, Dong MQ, Zhao PT, et al. Beta-estradiol attenuates hypoxic pulmonary hypertension by stabilizing the expression of p27kip1 in rats. Respir Res 2010;11:182.
45. Rabinovitch M, Gamble WJ, Miettinen OS, Reid L. Age and sex influence on pulmonary hypertension of chronic hypoxia and on recovery. Am J Physiol 1981;240:H62-H72.
46. Erzurum S, Rounds SI, Stevens T, Aldred M, Aliotta J, Archer SL, Asosingh K, Balaban R, Bauer N, Bhattacharya J, et al. Strategic plan for lung vascular research: an NHLBI-ORDR workshop report. Am J Respir Crit Care Med 2010;182:1554-1562.
47. Ziegler RG, Faupel-Badger JM, Sue LY, Fuhrman BJ, Falk RT, Boyd- Morin J, Henderson MK, Hoover RN, Veenstra TD, Keefer LK, et al. A new approach to measuring estrogen exposure and metabolism in epidemiologic studies. J Steroid Biochem Mol Biol 2010;121:538-545.
48. McMurtry IF, Frith CH, Will DH. Cardiopulmonary responses of male and female swine to simulated high altitude. J Appl Physiol 1973;35: 459-462.
49. Ergueta J, Spielvogel H, Cudkowicz L. Cardio-respiratory studies in chronic mountain sickness (Monge's syndrome). Respiration 1971; 28:485-517.
50. Hultgren HN, Lopez CE, Lundberg E, Miller H. Physiologic studies of pulmonary edema at high altitude. Circulation 1964;29:393-408.
51. Leon-Velarde F, Ramos MA, Hernandez JA, De Idiaquez D,Munoz LS, Gaffo A, Cordova S, Durand D, Monge C. The role of menopause in the development of chronic mountain sickness. Am J Physiol 1997; 272:R90-R94.
52. Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, Barst RJ, Benza RL, Liou TG, Turner M, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL registry. Chest 2010;137:376-387.
53. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010;122:156-163.
54. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, Frost A, Barst RJ, Badesch DB, Elliott CG, et al. Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL). Circulation 2010;122:164-172.
55. Humbert M, Sitbon O, Yaici A, Montani D, O'Callaghan DS, Jais X, Parent F, Savale L, Natali D, Gunther S, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010;36:549-555.
56. Shearman AM, Cooper JA, Kotwinski PJ, Humphries SE, Mendelsohn ME, Housman DE, Miller GJ. Estrogen receptor alpha gene variation and the risk of stroke. Stroke 2005;36:2281-2282. (Pubitemid 41429261)
57. Shearman AM, Cupples LA, Demissie S, Peter I, Schmid CH, Karas RH, Mendelsohn ME, Housman DE, Levy D. Association between estrogen receptor alpha gene variation and cardiovascular disease. JAMA 2003;290:2263-2270. (Pubitemid 37430558)
58. Peter I, Shearman AM, Vasan RS, Zucker DR, Schmid CH, Demissie S, Cupples LA, Kuvin JT, Karas RH, Mendelsohn ME, et al. Association of estrogen receptor beta gene polymorphisms with left ventricular mass and wall thickness in women. Am J Hypertens 2005;18:1388-1395. (Pubitemid 41566663)
59. Rajkumar R, Konishi K, Richards TJ, Ishizawar DC, Wiechert AC, Kaminski N, Ahmad F. Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension. Am J Physiol Heart Circ Physiol 2010;298:H1235-H1248.
60. Fliegner D, Schubert C, Penkalla A, Witt H, Kararigas G, Dworatzek E, Staub E, Martus P, Ruiz Noppinger P, Kintscher U, et al. Female sex and estrogen receptor-beta attenuate cardiac remodeling and apoptosis in pressure overload. Am J Physiol Regul Integr Comp Physiol 2010;298:R1597-R1606.
61. Lin J, Steenbergen C, Murphy E, Sun J. Estrogen receptor-beta activation results in S-nitrosylation of proteins involved in cardioprotection. Circulation 2009;120:245-254.
62. Wang M, Wang Y, Weil B, Abarbanell A, Herrmann J, Tan J, Kelly M, Meldrum DR. Estrogen receptor beta mediates increased activation of PI3K/AKT signaling and improved myocardial function in female hearts following acute ischemia. Am J Physiol Regul Integr Comp Physiol 2009;296:R972-R978.
63. Wang M, Crisostomo P, Wairiuko GM, Meldrum DR. Estrogen receptoralpha mediates acute myocardial protection in females. Am J Physiol Heart Circ Physiol 2006;290:H2204-H2209. (Pubitemid 43846046)
64. Kawut SM, Al-Naamani N, Agerstrand C, Rosenzweig EB, Rowan C, Barst RJ, Bergmann S, Horn EM. Determinants of right ventricular ejection fraction in pulmonary arterial hypertension. Chest 2009;135: 752-759.
65. Ventetuolo CE, Ouyang P, Bluemke DA, Tandri H, Barr RG, Bagiella E, Cappola AR, Bristow MR, Johnson C, Kronmal RA, et al. Sex hormones are associated with right ventricular structure and function: the MESA-right ventricle study. Am J Respir Crit Care Med 2011;183: 659-667.
66. Campo A, Mathai SC, Le Pavec J, Zaiman AL, Hummers LK, Boyce D, Housten T, Champion HC, Lechtzin N, Wigley FM, et al. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med 2010;182:252-260.
67. Ou LC, Sardella GL, Leiter JC, Brinck-Johnsen T, Smith RP. Role of sex hormones in development of chronic mountain sickness in rats. J Appl Physiol 1994;77:427-433. (Pubitemid 24226164)
68. Jilka RL, Passeri G, Girasole G, Cooper S, Abrams J, Broxmeyer H, Manolagas SC. Estrogen loss upregulates hematopoiesis in the mouse: a mediating role of IL-6. Exp Hematol 1995;23:500-506.
69. Mukundan H, Kanagy NL, Resta TC. 17-beta estradiol attenuates hypoxic induction of HIF-1alpha and erythropoietin in Hep3B cells. J Cardiovasc Pharmacol 2004;44:93-100. (Pubitemid 38857134)
70. Pare G, Krust A, Karas RH, Dupont S, Aronovitz M, Chambon P, Mendelsohn ME. Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury. Circ Res 2002;90:1087-1092. (Pubitemid 34627907)
71. Darblade B, Pendaries C, Krust A, Dupont S, Fouque MJ, Rami J, Chambon P, Bayard F, Arnal JF. Estradiol alters nitric oxide production in the mouse aorta through the alpha-, but not beta-, estrogen receptor. Circ Res 2002;90:413-419. (Pubitemid 34633910)
72. White K, Loughlin L, Maqbool Z, Nilsen M, McClure J, Dempsie Y, Baker AH, Maclean MR. The serotonin transporter, gender and hypoxia: microarray analysis in the pulmonary arteries of mice identifies genes with relevance to human PAH. Physiol Genomics 2011;43: 417-437.
73. White K, Dempsie Y, Nilsen M, Wright AF, Loughlin L, Maclean MR. The serotonin transporter, gender, and 17β oestradiol in the development of pulmonary arterial hypertension. Cardiovasc Res 2011;90: 373-382.
74. Thomas P, Dixon MS,Winterton SJ, Sheridan DJ. Acute haemodynamic effects of cromakalim in patients with angina pectoris. Br J Clin Pharmacol 1990;29:325-331. (Pubitemid 20129025)
75. Bray K, Quast U. Differences in the k(+)-channels opened by cromakalim, acetylcholine and substance P in rat aorta and porcine coronary artery. Br J Pharmacol 1991;102:585-594.
76. Porto CS, Lazari MF, Abreu LC, Bardin CW, Gunsalus GL. Receptors for androgen-binding proteins: internalization and intracellular signalling. J Steroid Biochem Mol Biol 1995;53:561-565.
77. Berthois Y, Katzenellenbogen JA, Katzenellenbogen BS. Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci USA 1986;83:2496-2500. (Pubitemid 16026909)
78. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008;132:27-42.
79. Meldrum DR. G-protein-coupled receptor 30 mediates estrogen's nongenomic effects after hemorrhagic shock and trauma. Am J Pathol 2007;170:1148-1151. (Pubitemid 47339323)
80. Filardo EJ, Quinn JA, Frackelton AR Jr, Bland KI. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and CAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol 2002;16:70-84. (Pubitemid 34044499)